Positioning no disclosures inside 60 days, left as found
Options no verdict drawn today, left as found
Ethical does not pass the values gate
Price12.56 USD
Fair value20.00
Ethical score70.0/100
Our investment reviews on this name
2026-10-02Read Markdown14.54-13.6% to today ✓Accumulation gives way to Markdown after a 10% slide in 4 weeks
2026-09-06Read Accumulation16.08-21.9% to today Distribution gives way to Accumulation with volume flow in agreement
2026-07-02Read Distribution15.64-19.7% to today ✓First review on file: Distribution
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
NeuroPace Inc holds its Markdown at $12.56. Elevated stress, defensive posture warranted, held for 86 days.
As held on the ledger · 2026-10-14
Phase
Markdown · caution
Quantitative state
Elevated stress, defensive posture warranted, held for 86 days
Price at the screen
$12.56
Valuation
N/A trailing · -54.10 forward price to earnings
Values screen
FAIL· score 70.0
Beta
1.89
The Workings
Five Screens, Shown in Full
Does not pass. Debt ratio
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
67.10%
Below 33%
Interest-bearing debt is 67.1% of its assets, above the one-third ceiling the screen allows.
Fail
Interest-bearing cash
37.29%
Below 33%
Interest-bearing cash and securities are 37.3% of assets, above the one-third limit.
Fail
Receivables
34.46%
Below 49%
Money owed to the company is 34.5% of assets, under the 49% limit.
Pass
Revenue purity
2.82%
Below 5%
Only 2.8% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Falls Short, in Plain English
NeuroPace's business is in a permissible area, but its interest-bearing debt is about 67% of the company, well over the ~33% line, so it does not pass on the financial screens.
Read as at 2026-10-25. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when NPCE's ethical verdict changes
Today NPCE does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
Fair value range in USD, drawn from the 2026-10-14 screen. The gold marker is the market price at the same screen. A 59.2% margin of safety to the base estimate.
Third-party analyst targets: 8 covering, consensus None. The average target sits +59% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-10-14 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market; it already moves more than the market on an average day; it carries a real debt load, which raises the stakes if revenue slips.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
NPCE trades on NASDAQ. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-10-25Markdown$12.56+0.0%Entry 8
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it D. Technically it is momentum reading bearish. Over the past year the shares are up 21%. Our forward projection puts the odds of a 10% gain over the next month near 38%. The street (8 analysts) rates it none, with a mean price target of $20.
2026-10-18Markdown$12.56-13.6%Entry 7
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 13.6% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 17% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 21%. Our forward projection puts the odds of a 10% gain over the next month near 38%. The street (8 analysts) rates it none, with a mean price target of $20.
2026-10-02Markdown · changed$14.54-9.6%Entry 6
The framework has shifted from accumulation to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 9.6% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 17% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 21%. Our forward projection puts the odds of a 10% gain over the next month near 38%. The street (8 analysts) rates it none, with a mean price target of $20. Since the last review it entered the Titan Ethical 500; its composite score rose.
The framework has shifted from distribution to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 17% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 21%. Our forward projection puts the odds of a 10% gain over the next month near 38%. The street (8 analysts) rates it none, with a mean price target of $20.
2026-08-07Distribution$16.08+2.8%Entry 4
Our analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved up 2.8% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 17% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 21%. Our forward projection puts the odds of a 10% gain over the next month near 38%. The street (8 analysts) rates it none, with a mean price target of $20.
2026-07-18Distribution$15.64+0.0%Entry 3
Our analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 17% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 21%. Our forward projection puts the odds of a 10% gain over the next month near 38%. The street (8 analysts) rates it none, with a mean price target of $20.
2026-07-03Distribution$15.64+0.0%Entry 2
Our analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows good risk-adjusted returns.
2026-07-02Distribution$15.64Entry 1
Our analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows good risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.